Clinical Trial Update: An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial evaluated biomarkers and safety of paquinimod (ABR-215757) in patients with systemic sclerosis. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Paquinimod (paquinimod)

Snippet

Sponsor: Active Biotech AB | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED